Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy

European Journal of Neurology

Volumn 20, Issue 5, 2013, Pages 836-842

  Markvardsen, L H ^a   Debost, J C ^a   Harbo, T ^a   Sindrup, S H ^b   Andersen, H ^a   Christiansen, I ^c   Otto, M ^a   Olsen, N K ^d   Lassen, L L ^e   Jakobsen, J ^a,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Chronic inflammatory demyelinating polyradiculoneuropathy; Pharmacology; Subcutaneous immunoglobulin

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PLACEBO; SODIUM CHLORIDE;

40 M WALKING TEST; ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRIP STRENGTH; HUMAN; INJECTION SITE REACTION; MALE; MEDICAL RESEARCH COUNCIL SCORE; MUSCLE STRENGTH; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROLOGICAL IMPAIRMENT SCORE; NINE HOLE PEG TEST; OVERALL DISABILITY SUM SCORE; PHYSICAL EXAMINATION; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; WALKING;

DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MUSCLE STRENGTH; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84876334249     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12080     Document Type: Article

References (29)

1. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009; 1: CD001797.
2. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2005; 2: CD004429.
3. Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20: 94-100.
4. Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991; 338: 162-166.
5. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst 2009; 14: 93-100.
6. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol 2009; 16: 631-638.
7. Cocito D, Serra G, Falcone Y, Paolasso I. The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst 2011; 16: 150-152.
8. Koller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006; 253: 1505-1506.
9. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008; 37: 406-409.
10. Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol 2009; 158(Suppl. 1): 51-59.
11. Merkies IS, Hughes RA, Donofrio P, et al. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst 2010; 15: 208-215.
12. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119(Pt 4): 1067-1077.
13. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-449.
14. Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996; 243: 280-285.
15. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990; 40: 209-212.
16. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993; 56: 36-39.
17. Andersen H. Reliability of isokinetic measurements of ankle dorsal and plantar flexors in normal subjects and in patients with peripheral neuropathy. Arch Phys Med Rehabil 1996; 77: 265-268.
18. Andersen H, Jakobsen J. A comparative study of isokinetic dynamometry and manual muscle testing of ankle dorsal and plantar flexors and knee extensors and flexors. Eur Neurol 1997; 37: 239-242.
19. Harbo T, Andersen H, Jakobsen J. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2008; 38: 1036-1045.
20. Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002; 72: 596-601.
21. Harbo T, Brincks J, Andersen H. Maximal isokinetic and isometric muscle strength of major muscle groups related to age, body mass, height, and sex in 178 healthy subjects. Eur J Appl Physiol 2012; 112: 267-275.
22. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-144.
23. Juel J, Markvardsen LH, Jakobsen J. Haemolytic anaemia as a complication to intravenous infusion of human immunoglobulin. Ugeskr Laeger 2011; 173: 1963-1964.
24. Kubori T, Mezaki T, Kaji R, et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No To Shinkei 1999; 51: 127-135.
25. Latov N, Deng C, Dalakas MC, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010; 67: 802-807.
26. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011; 7: 507-517.
27. Harbo T, Andersen H, Jakobsen J. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2009; 39: 439-447.
28. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139: 133-141.
29. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 2010; 75: 1377-1380.